231 related articles for article (PubMed ID: 26965862)
1. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
Kandil S; Westwell AD; McGuigan C
Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
[TBL] [Abstract][Full Text] [Related]
2. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
4. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
Kandil SB; Kariuki BM; McGuigan C; Westwell AD
Bioorg Med Chem Lett; 2021 Mar; 36():127817. PubMed ID: 33513386
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Kandil SB; McGuigan C; Westwell AD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
[TBL] [Abstract][Full Text] [Related]
8. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer.
Zhang W; Fan Y; Zhang Y; Feng Y; Luo Y; Zhou X; Chen Z; Wang C; Lu T; Tang F; Chen Y; Li H; Jiao Y
Bioorg Chem; 2024 Jul; 148():107433. PubMed ID: 38754311
[TBL] [Abstract][Full Text] [Related]
10. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
[TBL] [Abstract][Full Text] [Related]
11. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
Qin X; Fang L; Zhao J; Gou S
Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
[TBL] [Abstract][Full Text] [Related]
12. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
[TBL] [Abstract][Full Text] [Related]
13. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
14. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
19. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity.
Ouellette V; Côté MF; Gaudreault RC; Tajmir-Riahi HA; Bérubé G
Eur J Med Chem; 2019 Oct; 179():660-666. PubMed ID: 31279298
[TBL] [Abstract][Full Text] [Related]
20. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
